Michael Yang has taken up the position of CEO at ViaCyte, a private clinical-stage biotech.
ViaCyte is aiming to create the first islet cell replacement therapy for Type 1 diabetes and has two Phase 2 trials in that indication due to read out over the next 12 months.
Investors include Bain Capital, TPG and the J & J Innovation.
If ViaCyte’s Phase 2 results are positive and the venture capital backers were to seek an exit at that point via listing, Michael Yang would likely reap huge financial benefit.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)